A Phase I/IB Trial of MEK162 in Combination With Erlotinib in Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS or EGFR Mutation
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 24 Jul 2019
Price : $35 *
At a glance
- Drugs Binimetinib (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 29 May 2019 Status changed from recruiting to active, no longer recruiting.
- 15 Apr 2019 Planned primary completion date changed from 31 Mar 2019 to 31 Aug 2019.
- 23 Jun 2017 Planned End Date changed from 31 Dec 2017 to 31 Mar 2020.